Project Grant R21CA313071
Award Date 5/7/26
Completion Date 4/30/28
Dollars Obligated $401K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, DC 20057, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded $411,206 to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a project completion date of April 30, 2028. This Project Grant supports the development of small molecule inhibitors targeting the proton-sensing G protein-coupled receptor GPR68 as a novel therapeutic approach for pancreatic ductal adenocarcinoma (PDAC). The research addresses a critical clinical...
- Federal Grant Award Summary Purdue University received a $457,503 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on August 28, 2025, with completion targeted for July 31, 2030. The research project focuses on elucidating the posttranslational regulation of macropinocytosis in pancreatic ductal adenocarcinoma (PDAC), specifically investigating the role of protein phosphatase 2A (PP2A) subunit B56A in regulating nutrient-scavenging...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $391,826 to the University of Pennsylvania on July 16, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate an innovative nanoparticle-based therapeutic platform for breast cancer treatment. The project, which extends through June 30, 2027, focuses on designing biodegradable polyphosphazene nanoparticles (PPNPs) that combine heat shock protein (HSP) inhibitor drug...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $615,399 Project Grant to the University of California, Davis under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025, through July 31, 2030. The award supports the development of a transformable nanoparticle (TNP) platform designed to deliver therapeutic peptides and proteins directly to tumor microenvironments on-demand. The TNP technology transforms from nanoparticles to nanofibrils...
- Federal Grant Award Summary The University of Rochester received a $639,098 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and concluding July 31, 2030. This award supports research targeting intrinsic and extrinsic barriers to metastatic pancreatic ductal adenocarcinoma (PDAC) treatment. The project develops and evaluates an innovative combination therapy approach designed to overcome treatment resistance...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded $683,970 to The Trustees of Columbia University in the City of New York, Health Sciences Division on April 1, 2026, to support a five-year research project extending through March 31, 2031. This project focuses on tumor-penetrating stromal modification of αvβ5 integrin-rich pancreatic ductal adenocarcinoma (PDAC) through development and evaluation of the IRGD...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...
- Federal Project Grant Award Summary Columbia University's Health Sciences Division, in receipt of a $109,080 Project Grant awarded September 1, 2025, by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), is conducting a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The trial compares a four-drug regimen...
- Federal Grant Award Summary The University of Notre Dame DU Lac received a $551,601 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective June 10, 2025, through May 31, 2030. The research focuses on developing isoform-selective inhibitors targeting HSP90B (90 kilodalton heat shock protein), a chaperone protein involved in cancer progression. The project aims to create novel anti-cancer therapeutics that selectively inhibit...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Florida a $2,628,974 Project Grant on August 15, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate nanotechnology-enabled quantitative imaging technology for tracking dendritic cell (DC) anti-cancer vaccines. The research project, which extends through July 31, 2029, centers on magnetic particle imaging (MPI)—an innovative imaging modality utilizing...